Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials - PubMed (original) (raw)
Clinical Trial
doi: 10.1016/j.cllc.2017.06.016. Epub 2017 Jul 6.
James Moon 2, Antoinette J Wozniak 3, Philip Mack 4, Fred R Hirsch 5, Martin J Bury 6, Myron Kwong 7, Dorothy D Nguyen 8, Dennis F Moore 9, Jieling Miao 2, Mary Redman 2, Karen Kelly 4, David R Gandara 4
Affiliations
- PMID: 28801183
- PMCID: PMC5748264
- DOI: 10.1016/j.cllc.2017.06.016
Clinical Trial
Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials
Howard L West et al. Clin Lung Cancer. 2018 Jan.
Abstract
Background: Before mutation testing of the epidermal growth factor receptor (EGFR) gene was recognized as highly associated with the activity of EGFR tyrosine kinase inhibitors (TKIs), clinically defined patient populations with bronchioloalveolar carcinoma (BAC) and never smokers were identified as likely to benefit from EGFR TKIs. From preclinical and clinical data suggesting potentially improved efficacy with a combination of an EGFR TKI and the antiangiogenic agent bevacizumab, the Southwestern Oncology Group (SWOG) initiated paired phase II trials to evaluate the combination of erlotinib/bevacizumab in patients with advanced BAC (SWOG S0635) or never smokers with advanced lung adenocarcinoma (SWOG S0636).
Materials and methods: Eligible patients with BAC or adenocarcinoma with BAC features (SWOG S0635) or never smokers with advanced lung adenocarcinoma (SWOG S0636) received erlotinib 150 mg/day with bevacizumab 15 mg/kg until progression or prohibitive toxicity. Never smokers with BAC were preferentially enrolled to SWOG S0636. The primary endpoint for both trials was overall survival.
Results: A total of 84 patients were enrolled in the SWOG S0635 trial and 85 in the SWOG S0636 trial. The objective response rate was 22% (3% complete response) in the SWOG S0635 trial and 50% (38% confirmed; 3% complete response) in the SWOG S0636 trial. The median progression-free survival was 5 and 7.4 months in the S0635 and S0636 trials, respectively. The median overall survival was 21 and 29.8 months, respectively. Toxicity consisted mainly of rash and diarrhea in both trials.
Conclusion: Although the field has moved toward molecular, rather than clinical, selection of patients as optimal candidates for EGFR TKI therapy, these results support the hypothesis that a subset of patients in whom erlotinib is particularly active could receive an incremental benefit from the addition of bevacizumab.
Keywords: Antiangiogenesis; BAC; Bronchioloalveolar; EGFR; Lepidic; Never-smoker.
Copyright © 2017 Elsevier Inc. All rights reserved.
Figures
Figure 1
Progression-Free Survival Kaplan-Meier curves for progression-free survival on S0635 (panel A) and S0636 (panel B)
Figure 2
Overall Survival Kaplan-Meier curves for overall survival on S0635 (panel A) and S0636 (panel B)
Figure 3
Waterfall plots for measurable response Waterfall plots for objective tumor response on S0635 (panel A) and S0636 (panel B)
Comment in
- VEGF inhibitors in _EGFR_-mutated lung cancer: a never-ending story?
Alexander M, Halmos B. Alexander M, et al. Ann Transl Med. 2018 Dec;6(23):446. doi: 10.21037/atm.2018.11.20. Ann Transl Med. 2018. PMID: 30603634 Free PMC article. No abstract available.
References
- Mok TS, Wu Y-L, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. New Engl J Med. 2009;361:947–957. -PubMed
- Miller VA, Kris MG, Shah N, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small- cell lung cancer. J Clin Oncol. 2004;22:1103–1109. -PubMed
- Gandara DR, West H, Chansky K, et al. Bronchioloalveolar carcinoma: A model for investigating the biology of EGFR Inhibition. Clin Cancer Res. 2004;10:4205s–4209s. -PubMed
- Subramanian J, Govindan R. Lung cancer in never-smokers: a review. J Clin Oncol. 2007;25:561–570. -PubMed
Publication types
MeSH terms
Substances
Grants and funding
- U10 CA016385/CA/NCI NIH HHS/United States
- UG1 CA189821/CA/NCI NIH HHS/United States
- N01 CA032102/CA/NCI NIH HHS/United States
- U10 CA058416/CA/NCI NIH HHS/United States
- UG1 CA233324/CA/NCI NIH HHS/United States
- U10 CA046282/CA/NCI NIH HHS/United States
- U10 CA073590/CA/NCI NIH HHS/United States
- UG1 CA189997/CA/NCI NIH HHS/United States
- U10 CA180888/CA/NCI NIH HHS/United States
- UG1 CA189971/CA/NCI NIH HHS/United States
- U10 CA012644/CA/NCI NIH HHS/United States
- U10 CA180834/CA/NCI NIH HHS/United States
- UG1 CA189848/CA/NCI NIH HHS/United States
- UG1 CA189872/CA/NCI NIH HHS/United States
- UG1 CA189822/CA/NCI NIH HHS/United States
- N01 CA035119/CA/NCI NIH HHS/United States
- U10 CA180846/CA/NCI NIH HHS/United States
- UG1 CA189858/CA/NCI NIH HHS/United States
- UG1 CA189860/CA/NCI NIH HHS/United States
- UG1 CA189830/CA/NCI NIH HHS/United States
- UG1 CA189954/CA/NCI NIH HHS/United States
- U10 CA045450/CA/NCI NIH HHS/United States
- U10 CA032102/CA/NCI NIH HHS/United States
- N01 CA038926/CA/NCI NIH HHS/United States
- U10 CA180818/CA/NCI NIH HHS/United States
- UG1 CA233340/CA/NCI NIH HHS/United States
- U10 CA038926/CA/NCI NIH HHS/United States
- U10 CA035119/CA/NCI NIH HHS/United States
- UG1 CA189808/CA/NCI NIH HHS/United States
- U10 CA180819/CA/NCI NIH HHS/United States
- UG1 CA189953/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous